CHRS
Price
$1.50
Change
+$0.05 (+3.45%)
Updated
Sep 26 closing price
Capitalization
174.34M
44 days until earnings call
XNCR
Price
$11.57
Change
+$1.24 (+12.00%)
Updated
Sep 26 closing price
Capitalization
825.21M
44 days until earnings call
Interact to see
Advertisement

CHRS vs XNCR

Header iconCHRS vs XNCR Comparison
Open Charts CHRS vs XNCRBanner chart's image
Coherus Oncology
Price$1.50
Change+$0.05 (+3.45%)
Volume$1.57M
Capitalization174.34M
Xencor
Price$11.57
Change+$1.24 (+12.00%)
Volume$1.06M
Capitalization825.21M
CHRS vs XNCR Comparison Chart in %
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. XNCR commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a StrongBuy and XNCR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (CHRS: $1.50 vs. XNCR: $11.57)
Brand notoriety: CHRS and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 110% vs. XNCR: 116%
Market capitalization -- CHRS: $174.34M vs. XNCR: $825.21M
CHRS [@Biotechnology] is valued at $174.34M. XNCR’s [@Biotechnology] market capitalization is $825.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 1 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • CHRS’s FA Score: 1 green, 4 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, CHRS is a better buy in the long-term than XNCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 6 bullish TA indicator(s).

  • CHRS’s TA Score: 4 bullish, 4 bearish.
  • XNCR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, XNCR is a better buy in the short-term than CHRS.

Price Growth

CHRS (@Biotechnology) experienced а -6.83% price change this week, while XNCR (@Biotechnology) price change was +12.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

CHRS is expected to report earnings on Nov 10, 2025.

XNCR is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XNCR($825M) has a higher market cap than CHRS($174M). CHRS YTD gains are higher at: 8.696 vs. XNCR (-49.652). CHRS has higher annual earnings (EBITDA): 88.2M vs. XNCR (-125.38M). XNCR has more cash in the bank: 444M vs. CHRS (238M). CHRS has less debt than XNCR: CHRS (41M) vs XNCR (67.9M). CHRS has higher revenues than XNCR: CHRS (272M) vs XNCR (147M).
CHRSXNCRCHRS / XNCR
Capitalization174M825M21%
EBITDA88.2M-125.38M-70%
Gain YTD8.696-49.652-18%
P/E Ratio2.83N/A-
Revenue272M147M185%
Total Cash238M444M54%
Total Debt41M67.9M60%
FUNDAMENTALS RATINGS
CHRS vs XNCR: Fundamental Ratings
CHRS
XNCR
OUTLOOK RATING
1..100
8026
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
597
PRICE GROWTH RATING
1..100
3746
P/E GROWTH RATING
1..100
846
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHRS's Valuation (35) in the Biotechnology industry is somewhat better than the same rating for XNCR (84). This means that CHRS’s stock grew somewhat faster than XNCR’s over the last 12 months.

CHRS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as XNCR (100). This means that CHRS’s stock grew similarly to XNCR’s over the last 12 months.

CHRS's SMR Rating (5) in the Biotechnology industry is significantly better than the same rating for XNCR (97). This means that CHRS’s stock grew significantly faster than XNCR’s over the last 12 months.

CHRS's Price Growth Rating (37) in the Biotechnology industry is in the same range as XNCR (46). This means that CHRS’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for CHRS (84). This means that XNCR’s stock grew significantly faster than CHRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSXNCR
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
N/A
Bullish Trend 6 days ago
72%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 4 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 9 days ago
73%
Bullish Trend 6 days ago
71%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 19 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
KSMIX9.960.13
+1.32%
Keeley Gabelli SMID Cap Value I
TRREX11.420.11
+1.00%
T. Rowe Price Real Estate
MENAX9.020.06
+0.67%
Madison Covered Call & Equity Income A
DIFEX12.470.02
+0.16%
MFS Diversified Income R2
VSMIX28.16N/A
N/A
Invesco Small Cap Value Y

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with XENE. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+3.45%
XENE - CHRS
40%
Loosely correlated
+4.00%
XNCR - CHRS
37%
Loosely correlated
+12.00%
RXRX - CHRS
34%
Loosely correlated
+1.94%
DNA - CHRS
34%
Loosely correlated
+2.22%
SRRK - CHRS
33%
Loosely correlated
+12.35%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with CRNX. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
+12.00%
CRNX - XNCR
62%
Loosely correlated
+27.92%
DYN - XNCR
58%
Loosely correlated
+4.53%
SYRE - XNCR
56%
Loosely correlated
+4.04%
CGON - XNCR
56%
Loosely correlated
+2.91%
NUVL - XNCR
56%
Loosely correlated
+4.99%
More